Print

IAVI D001

A randomised, placebo-controlled, dose-escalating phase I double-blinded study to evaluate the safety and immunogenicity of TBC-M4 (Modified Vaccinia Ankara (MVA) HIV-1 multigenic subtype C) vaccine in HIV-uninfected, healthy volunteers

Trial Details:

I Completed
International AIDS Vaccine Initiative (IAVI), Therion December 01, 2005
TBC-M4 Pox env, gag, tat-rev, and nef-RT C
TBC-M4 Viral Vector - Pox
India 32
http://www.iavi.org